Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donafenib + tislelizumab
- Development stage
- Phase 2
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of donafenib, an oral multikinase inhibitor targeting VEGFR, PDGFR, and Raf kinases, and tislelizumab, a humanized IgG4 monoclonal antibody targeting PD-1. This combination aims to suppress tumor cell proliferation and angiogenesis while enhancing immune response against tumor cells. The combination is being investigated in clinical trials for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC).
02
Targets
BRAF V600EVEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))
Beyond the preview
Go deeper on donafenib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donafenib + tislelizumab.